<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02143050</url>
  </required_header>
  <id_info>
    <org_study_id>BCC-MEL-14-01</org_study_id>
    <nct_id>NCT02143050</nct_id>
  </id_info>
  <brief_title>Study of Dabrafenib, Trametinib and Metformin for Melanoma Patients</brief_title>
  <official_title>A Phase I/II Trial of Dabrafenib, Trametinib and Metformin Administered to Unresectable Stage IIIC and Stage IV BRAF V600E + Melanoma Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Louisville</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>James Graham Brown Cancer Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Louisville</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main purpose is to evaluate the clinical response, safety and survival of the FDA&#xD;
      approved drugs Dabrafenib, Trametinib in combination with Metformin. Investigators&#xD;
      hypothesize that the combination of an FDA approved non toxic dose of oral Metformin with the&#xD;
      B-Raf inhibitor, Dabrafenib and the MEK inhibitor, Trametinib will yield little toxicity and&#xD;
      improve clinical outcomes in terms of objective response rates and survival in metastatic&#xD;
      melanoma patients.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study will be a single-arm, single center, uncontrolled phase I/II trial to estimate the&#xD;
      safety of the combined treatments and then estimate the efficacy in terms of objective&#xD;
      response rate in patients with stage IIIC and Stage IV melanoma treated with&#xD;
      dabrafenib/trametinib and metformin.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>September 2014</start_date>
  <completion_date type="Anticipated">June 2026</completion_date>
  <primary_completion_date type="Anticipated">June 2024</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Observation of two CTCAE drug related grade 4 toxicities in six patients.</measure>
    <time_frame>Duration of phase I portion, approxiately 6 months</time_frame>
    <description>During phase I, six patients will be enrolled and monitored for toxicities. If drug related deaths occur or more than two drug related CTCAE grade 4 toxicities occur the trial will be suspended. Phase II will estimate the efficacy of the drugs, enrolling 20 patients during stage 1 with an upper limit of 39 for the 2nd stage.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Clinical Response Rate</measure>
    <time_frame>6 years</time_frame>
    <description>Phase II will study the efficacy of the drugs enrolling 20 patients during stage I with an upper limit of 39 for the 2nd stage.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>To estimate the overall survival rates.</measure>
    <time_frame>Approximately 3 years</time_frame>
    <description>Patients will be contacted every 3 months following treatment administration for up to three years to obtain survival data.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To explore the effect of other covariates on overall survival</measure>
    <time_frame>3 years</time_frame>
    <description>To identify demographic, disease and treatment related effects on overall survival.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">53</enrollment>
  <condition>Melanoma</condition>
  <arm_group>
    <arm_group_label>Dabrafenib, Trametinib and Metformin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dabrafenib 150 mg PO BID until progression or unacceptable toxicity. Trametinib 2 mg PO QD until progression or unacceptable toxicity. Metformin 500 mg PO BID x 2 weeks, then 850 mg PO BID until progression or unacceptable toxicity.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dabrafenib</intervention_name>
    <arm_group_label>Dabrafenib, Trametinib and Metformin</arm_group_label>
    <other_name>Tafinlar</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Trametinib</intervention_name>
    <arm_group_label>Dabrafenib, Trametinib and Metformin</arm_group_label>
    <other_name>Mekinist</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Metformin</intervention_name>
    <arm_group_label>Dabrafenib, Trametinib and Metformin</arm_group_label>
    <other_name>Glucophage</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male or female patients &gt; 18 years of age&#xD;
&#xD;
          -  Patients with histologically confirmed BRAFV600E melanoma (Stage IIIC or&#xD;
&#xD;
          -  Stage IV, American Joint Commission on Cancer)&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group Performance Status of 0 to 2&#xD;
&#xD;
          -  Life expectancy &gt; 3 months&#xD;
&#xD;
          -  At least 1 site of radiographically measurable disease by RECIST 1.1&#xD;
&#xD;
          -  Adequate hematologic, renal, and liver function as defined by laboratory values&#xD;
             performed within 42 days prior to initiation of dosing:&#xD;
&#xD;
          -  Absolute neutrophil count &gt; 1.0 x 10⁹/L&#xD;
&#xD;
          -  Platelet count &gt; 50 x 10⁹/L&#xD;
&#xD;
          -  Hemoglobin &gt; 8 g/dL&#xD;
&#xD;
          -  Serum creatinine &lt; 2 x upper limit of normal&#xD;
&#xD;
          -  Total serum bilirubin &lt; 3 x ULN&#xD;
&#xD;
          -  Serum aspartate transaminase or serum alanine transaminase &lt; 3 x ULN, and &lt; 4 x ULN if&#xD;
             liver metastases are present&#xD;
&#xD;
          -  Fertile males should use an effective method of contraception during treatment and for&#xD;
             at least 3 months after completion of treatment, as directed by their physician&#xD;
&#xD;
          -  Pre-menopausal females and females &lt; 2 years after the onset of menopause should have&#xD;
             a negative pregnancy test at Screening. Pre-menopausal females must agree to use an&#xD;
             acceptable method of birth control from the time of the negative pregnancy test up to&#xD;
             90 days after the last dose of the study drug&#xD;
&#xD;
          -  Females of non-childbearing potential may be included if they are either surgically&#xD;
             sterile or have been postmenopausal for &gt; 1 year&#xD;
&#xD;
          -  Before study entry, written informed consent must be obtained from the patient prior&#xD;
             to performing any study related procedures&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Prior treatment with Vemurafenib or Dabrafenib&#xD;
&#xD;
          -  Known hypersensitivity to Metformin or any of its components&#xD;
&#xD;
          -  Received radiotherapy for non CNS disease within the 2 weeks prior to commencing study&#xD;
             treatment or have not recovered from side effects of all radiation related toxicities&#xD;
             to Grade &lt; 1, except for alopecia&#xD;
&#xD;
          -  Pregnant, breast feeding, or refusing double barrier contraception, oral&#xD;
             contraceptives, or avoidance of pregnancy measures&#xD;
&#xD;
          -  Have any other uncontrolled infection or medical condition that could interfere with&#xD;
             the conduct of the study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>100 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jason A Chesney, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>James Graham Brown Cancer Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Stacy Baum, BSN</last_name>
    <phone>502-562-2280</phone>
    <email>msbaum02@louisville.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Karen Carter, BSN</last_name>
    <phone>502-562-3690</phone>
    <email>kmcart05@louisville.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>James Graham Brown Cancer Center-Universityof Louisville</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jason A Chesney, MD, PhD</last_name>
      <phone>502-562-3429</phone>
      <email>jason.chesney@louisville.edu</email>
    </contact>
    <contact_backup>
      <last_name>Christina LaDuke</last_name>
      <phone>502-217-5205</phone>
      <email>christy.laduke@louisville.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Donald M Miller, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Kelly M McMasters, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Sucheta Telang, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>James Graham Brown Cancer Center</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Karen Carter, BSN</last_name>
      <phone>502-562-3690</phone>
      <email>kmcart05@louisville.edu</email>
    </contact>
    <contact_backup>
      <last_name>Christina LaDuke, BS</last_name>
      <phone>502-217-5205</phone>
      <email>christi.laduke@louisville.edu</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>May 13, 2014</study_first_submitted>
  <study_first_submitted_qc>May 18, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 20, 2014</study_first_posted>
  <last_update_submitted>October 22, 2021</last_update_submitted>
  <last_update_submitted_qc>October 22, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 29, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Louisville</investigator_affiliation>
    <investigator_full_name>Jason Chesney</investigator_full_name>
    <investigator_title>Director, James Graham Brown Cancer Center</investigator_title>
  </responsible_party>
  <keyword>Unresectable melanoma Stage IIIC and Stage IV BRAF V600E+</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Melanoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Metformin</mesh_term>
    <mesh_term>Trametinib</mesh_term>
    <mesh_term>Dabrafenib</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

